Skip to main content
. 2024 May 17;16(5):799. doi: 10.3390/v16050799

Figure 2.

Figure 2

Persistent increase of CD8 T cell-mediated virus control after anti-PD-L1 antibody treatment of chronic LCMV-infected mice. (a) Schematic representation of anti-PD-L1 (aPDL1) antibody treatment in chronic LCMV-infected mice. Untreated chronic infected mice were used as controls (ctr) and sampled at the same time point as the anti-PD-L1-treated mice. (b) Frequencies of LCMV gp33-responsive IFNγ-producing CD8+ T cells at day 60 post-infection and 30 days after the last aPDL1 treatment. (c) Viral loads in serum from day 60 post-infection, after aPDL1 treatment. (d) Spleen fibrosis score from day 60 post-infection. Data shown are the mean of n = 5 to 6 mice. * p ≤ 0.05; ns = not significant (unpaired two-tailed t-test).